Role of the Gut Microbiota in the Development of Urolithiasis
V. N. Pavlov,
A. M. Pushkarev,
S. Sh. Sabirzyanov,
V. V. Sergeev,
V. V. Churbakov,
G. R. Gazizullina,
I. A. Gimranova,
L. R. Khakimova https://doi.org/10.35401/2541-9897-2024-9-3-111-116
Abstract
This article aims to review the literature regarding assessment of the gut microbiota effect on kidney stone formation. We sought to determine whether several specific gut bacteria or a wider number of members of the gut microbiota are responsible for this association based on the literature data. We conducted an extensive literature search (publications on kidney stones and gut microbiota dated 2013-2023) in PubMed, Cochrane CENTRAL, and Web of Science Core Collection.
A large number of earlier studies were focused on physical and chemical properties of crystals formed by kidney stones. In recent years as diagnostic technologies advance, there has been a tendency to study the association of the gut microbiota and the development of other unrelated diseases. Studies have emerged showing the gut microbiota effect on the development of urolithiasis, which suggests that stone formation can be prevented or caused by changing the structure of the gut microbiome. However, further research is needed to identify which genera or types of the gut microbiota break down oxalate and reduce the risk of kidney stone formation.
About the Authors
V. N. Pavlov
Bashkir State Medical University
Russian Federation
Russian Federation
Valentin N. Pavlov, Dr. Sci. (Med.), Professor, Academician
of the Russian Academy of Sciences, Head of the Urology and Oncology Department
A. M. Pushkarev
Bashkir State Medical University
Russian Federation
Russian Federation
Aleksey M. Pushkarev, Dr. Sci. (Med.), Professor at the
Urology and Oncology Department,
ulitsa Lenina 3, Ufa, 450077
S. Sh. Sabirzyanov
Bashkir State Medical University
Russian Federation
Russian Federation
Sabir Sh. Sabirzyanov, Resident, Urology and Oncology Department
V. V. Sergeev
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Vladimir V. Sergeev, Cand. Sci. (Med.), Head of the Urology
Unit No. 1
V. V. Churbakov
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Vasiliy V. Churbakov, Urologist, Urology Unit No. 1
G. R. Gazizullina
Bashkir State Medical University
Russian Federation
Russian Federation
Gulnara R. Gazizullina, Head of the Laboratory of Human
Microbiome
I. A. Gimranova
Bashkir State Medical University
Russian Federation
Russian Federation
Irina A. Gimranova, Cand. Sci. (Med.), Head of the Department of Fundamental and Applied Microbiology
L. R. Khakimova
Bashkir State Medical University
Russian Federation
Russian Federation
Liliya R. Khakimova, Cand. Sci. (Bio.), Associate Professor at the Department of Fundamental and Applied Microbiology
References
1. Russian Society of Urology. Clinical Guidelines. Urolithiasis. Russian Society of Urologists; 2020. (In Russ.).
2. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320. PMID: 28213860. https://doi.org/10.1007/s00345-017-2008-6
3. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333–344. PMID: 16443041. https://doi.org/10.1016/S0140-6736(06)68071-9
4. Buttó LF, Haller D. Dysbiosis in Crohn’s disease - joint action of stochastic injuries and focal inflammation in the gut. Gut Microbes. 2017;8(1):53–58. PMID: 28102757. PMCID: PMC5341912. https://doi.org/10.1080/19490976.2016.1270810
5. Miller AW, Choy D, Penniston KL, Lange D. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis. Kidney Int. 2019;96(1):180– 188. PMID: 31130222. PMCID: PMC6826259. https://doi.org/10.1016/j.kint.2019.02.012
6. Singh P, Enders FT, Vaughan LE, et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–1365. PMID: 26349951. PMCID: PMC4593754. https://doi.org/10.1016/j. mayocp.2015.07.016
7. Dhondup T, Kittanamongkolchai W, Vaughan LE, et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis. 2018;72(6):790–797. PMID: 30146423. PMCID: PMC6252145. https://doi.org/10.1053/j.ajkd.2018.06.012
8. Shoag J, Halpern J, Goldfarb DS, Eisner BH. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol. 2014;192(5):1440–1445. PMID: 24929140. https://doi.org/10.1016/j.juro.2014.05.117
9. Brzica H, Breljak D, Burckhardt BC, Burckhardt G, Sabolić I. Oxalate: from the environment to kidney stones. Arh Hig Rada Toksikol. 2013;64(4):609–630. PMID: 24384768. https://doi. org/10.2478/10004-1254-64-2013-2428
10. Ferraro PM, Bargagli M, Trinchieri A, Gambaro G. Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets. Nutrients. 2020;12(3):779. PMID: 32183500. PMCID: PMC7146511. https://doi.org/10.3390/nu12030779
11. Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol. 2020;17(7):407–421. PMID: 32533118. https://doi.org/10.1038/s41585-020-0332-x
12. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. PMID: 27188687. PMCID: PMC5685519. https://doi.org/10.1038/nrdp.2016.8
13. Xiang L, Jin X, Liu Y, et al. Prediction of the occurrence of calcium oxalate kidney stones based on clinical and gut microbiota characteristics. World J Urol. 2022;40(1):221–227. PMID: 34427737. PMCID: PMC8813786. https://doi.org/10.1007/s00345-021-03801-7
14. Yuan T, Xia Y, Li B, et al. Gut microbiota in patients with kidney stones: a systematic review and meta-analysis. BMC Microbiol. 2023;23(1):143. PMID: 37208622. PMCID: PMC10197343. https://doi.org/10.1186/s12866-023-02891-0
15. Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009;103(1):18–21. PMID: 19021605. https://doi.org/10.1111/j.1464-410X.2008.08122.x
16. Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83(6):1144–1149. PMID: 23536130. https://doi.org/10.1038/ki.2013.104
17. Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018;46(6):503–514. PMID: 29353409. https://doi.org/10.1007/s00240-018-1037-y
18. Stern JM, Moazami S, Qiu Y, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis. 2016;44(5):399–407. PMID: 27115405. PMCID: PMC8887828. https://doi.org/10.1007/s00240-016-0882-9
19. Kim HN, Kim JH, Chang Y, et al. Gut microbiota and the prevalence and incidence of renal stones. Sci Rep. 2022;12(1):3732. PMID: 35260689. PMCID: PMC8904816. https://doi.org/10.1038/ s41598-022-07796-y
20. Cao C, Fan B, Zhu J, Zhu N, Cao JY, Yang DR. Association of gut microbiota and biochemical features in a Chinese population with renal uric acid stone. Front Pharmacol. 2022;13:888883. PMID: 35662733. PMCID: PMC9160931. https://doi.org/10.3389/fphar.2022.888883
21. Ticinesi A, Milani C, Guerra A, et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018;67(12):2097–2106. PMID: 29705728. https://doi.org/10.1136/gutjnl-2017-315734
22. Tavasoli S, Alebouyeh M, Naji M, et al. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study. BJU Int. 2020;125(1):133–143. PMID: 31145528. https://doi.org/10.1111/bju.14840
23. Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29. PMID: 28217694. PMCID: PMC5300857. https://doi.org/10.21037/atm.2016.11.86
24. Denburg MR, Koepsell K, Lee JJ, Gerber J, Bittinger K, Tasian GE. Perturbations of the gut microbiome and metabolome in children with calcium oxalate kidney stone disease. J Am Soc Nephrol. 2020;31(6):1358–1369. PMID: 32381601. PMCID: PMC7269359. https://doi.org/10.1681/ASN.2019101131
25. Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016;6:34712. PMID: 27708409. PMCID: PMC5052600. https://doi.org/10.1038/srep34712
26. Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K. The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature. BMC Nephrol. 2020;21(1):215. PMID: 32503496. PMCID: PMC7275316. https://doi.org/10.1186/s12882-020-01805-w
27. Chen F, Bao X, Liu S, et al. Gut microbiota affect the formation of calcium oxalate renal calculi caused by high daily tea consumption. Appl Microbiol Biotechnol. 2021;105(2):789–802. PMID: 33404827. https://doi.org/10.1007/s00253-020-11086-w
28. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea--a review. J Am Coll Nutr. 2006;25(2):79–99. PMID: 16582024. https://doi.org/10.1080/07315724.2006.10719518
29. Yang Y, Zhang X, Weng PF, Wu ZF. In vitro monitoring of the probiotic activity of tea catechins on human intestinal flora. Modern Food Science and Technology. 2015;31(4):128–136.
30. Tasian GE, Jemielita T, Goldfarb DS, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018;29(6):1731–1740. PMID: 29748329. PMCID: PMC6054354. https://doi.org/10.1681/ASN.2017111213
31. Wang Y, Sun J, Xie S, et al. Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats. Front Cell Infect Microbiol. 2023;13:1145196. PMID: 37313343. PMCID: PMC10258309. https://doi.org/10.3389/fcimb.2023.1145196
32. Mehra Y, Rajesh NG, Viswanathan P. Analysis and characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: two probiotic bacteria that can degrade intestinal oxalate in hyperoxaluric rats. Probiotics Antimicrob Proteins. 2022;14(5):854–872. PMID: 35699895. https://doi.org/10.1007/s12602-022-09958-w
33. Tian L, Liu Y, Xu X, et al. Lactiplantibacillus plantarum J-15 reduced calcium oxalate kidney stones by regulating intestinal microbiota, metabolism, and inflammation in rats. FASEB J. 2022;36(6):e22340. PMID: 35524736. https://doi.org/10.1096/ fj.202101972RR
34. Wu F, Cheng Y, Zhou J, et al. Zn2+ regulates human oxalate metabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones. Int J Biol Macromol. 2023;234:123320. PMID: 36682657. https://doi.org/10.1016/j.ijbiomac.2023.123320
Review
For citations:
Pavlov V.N., Pushkarev A.M., Sabirzyanov S.Sh., Sergeev V.V., Churbakov V.V., Gazizullina G.R., Gimranova I.A., Khakimova L.R. Role of the Gut Microbiota in the Development of Urolithiasis. Innovative Medicine of Kuban. 2024;(3):111-116. (In Russ.) https://doi.org/10.35401/2541-9897-2024-9-3-111-116
Views:
439
Email this article 
